

# Contents

---

Foreword .....	.ix
Acknowledgments .....	.xi
Abbreviations and Acronyms .....	.xv
Executive Summary .....	.3
<b>1 Introduction .....</b>	<b>.11</b>
<b>2 Rationale for a Renewed World Bank Effort on Malaria .....</b>	<b>.13</b>
2.1 Malaria Impairs Economic Growth and Human Development .....	.14
2.2 Malaria Is Preventable and Curable, with Good Returns on Investment .....	.15
2.3 Success Is Possible on a Large Scale .....	.16
2.4 There is a Wide Gap between Knowing and Doing .....	.18
2.5 The World Bank Has Underused its Comparative Advantage in Malaria Control .....	.24
2.6 Clients and Partners Demand a Stronger World Bank Effort .....	.34
<b>3 Priorities and Business Model .....</b>	<b>.37</b>
<b>4 Program of Action .....</b>	<b>.43</b>
4.1 The Program and Deliverables .....	.43
4.2 The International Finance Corporation and the Private Sector in Malaria Control .....	.45
4.3 Cooperation with the Global Fund and Other Major Partners in Malaria Control .....	.50
<b>5 The Malaria Task Force .....</b>	<b>.53</b>
5.1 Objectives .....	.53
5.2 Oversight .....	.54
5.3 Staffing: Secretariat and Regional Clusters .....	.54
5.4 Financing the Malaria Task Force .....	.54
<b>6 Results-Based Monitoring and Evaluation .....</b>	<b>.57</b>
6.1 Results Framework .....	.57
6.2 Steps to a Results-Based Monitoring and Evaluation System .....	.58
6.3 RBM Technical Strategies and Indicators of Population Coverage .....	.59
<b>Appendix 1 Outline of the Monitoring and Evaluation Framework .....</b>	<b>.61</b>
A1.1 Support to Countries .....	.61
A1.2 Support to Regional/Global Partnerships and Collective Efforts .....	.63
A1.3 Strengthening of Bank's Capacity to Contribute Effectively to Malaria Control .....	.64

**Rolling Back Malaria**

Appendix 2	Malarial Case Notification and Coverage with Key Interventions	.67
	Notes on Available Information	.67
	Data Tables	
1	Malarial Case Notification: Malaria Notifications for the Most Recent Year Information Received	.70
2	Malarial Case Notification: Standardized Malaria Notifications and Notification Rates per 1,000, since 1990	.80
3	Percentage of Households That Have at Least One Mosquito Net, by Background Characteristics	.96
4	Percentage of Households That Have at Least One Insecticide-treated Mosquito Net, by Background Characteristics	100
5	Percentage of Children under Five Years Old That Slept under a Mosquito Net during the Night Preceding the Survey, by Background Characteristics	104
6	Percentage of Children under Five Years Old That Slept under an Insecticide-treated Mosquito Net during the Night Preceding the Survey, by Background Characteristics	110
7	Percentage of Pregnant Women That Slept under a Mosquito Net during the Night Preceding the Survey, by Background Characteristics	116
8	Percentage of Pregnant Women That Slept under an Insecticide-treated Mosquito Net during the Night Preceding the Survey, by Background Characteristics	118
9	Pregnant Women Receiving Sulfadoxine Pyrimethamine (SP) at Least Once during Pregnancy (Community Level, Prevention or Treatment), by Background Characteristics	120
10	Pregnant Women Receiving Sulfadoxine Pyrimethamine (SP) at Least Twice during Pregnancy (Community Level, Prevention or Treatment), by Background Characteristics	120
11	Pregnant Women Receiving Sulfadoxine Pyrimethamine (SP) at Least Once during an Antenatal Visit, by Background Characteristics	122
12	Pregnant Women Receiving Sulfadoxine Pyrimethamine (SP) at Least Twice during an Antenatal Visit, by Background Characteristics	122
13	Percentage of Children under Five Years Old with Reported Fever in the Two Weeks Prior to the Survey, by Background Characteristics	124
14	Percentage of Febrile Children under Five Years Old That Received Treatment with Chloroquine, by Background Characteristics	132
15	Percentage of Febrile Children under Five Years Old That Received Treatment with Sulfadoxine Pyrimethamine (SP), by Background Characteristics	136

16	Percentage of Febrile Children under Five Years Old That Received Treatment with Any Antimalarial, by Background Characteristics	140
17	Summary of Antimalarial Drug Efficacy Results, Expressed as Treatment Failure	144
Appendix 3	Four Success Stories: Malaria Control in Brazil, Eritrea, India, and Vietnam	157
Appendix 4	Strategic Communications	171
Appendix 5	High-Impact Partnerships: Private Sector and Civil Society	175
Appendix 6	Impact of Malaria on Schoolchildren and the Education Sector	179
Notes		181
References		183
Tables, Figures, and Boxes		
Box 1	Malaria and Selected MDGs	4
Figure 2.1	Profile in Contrasts: The Persistent Burden of Malaria in Africa	17
Table 2.1	Ownership of Insecticide-treated Bed Nets in Malawi, by Income Group	19
Figure 2.2	Access to Antimalarial Treatment	20
Figure 2.3	The Increasing Costs of Commodities for Malaria Control	24
Figure 2.4	Effectiveness of PRSPs in Addressing Malaria	29
Figure 2.5	Malaria Control Efforts Have Not Benefited from Increased Health Spending in Ghana	33
Table 3.1	The Booster Program for Malaria Control: Matrix of Options for Financing and Instruments	41
Box 2.1	Putting the Bank's Comparative Advantage to Work: Assisting Countries to Develop Strategies for Financing Treatment with ACTs	45
Table 4.1	The Booster Program for Malaria: Deliverables	46
Table 5.1	Potential Staffing and Distribution of the Malaria Task Force	55

## Foreword

---

Malaria afflicts millions in low- and middle-income countries. For centuries, it has impaired economic growth, child development, learning, health, and productivity on a large scale. The World Bank has worked to reduce the burden of malaria, together with many partner agencies. In 1998 the Bank cofounded, with the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), and the United Nations Development Program (UNDP), the global Roll Back Malaria (RBM) Partnership to coordinate and enhance the global fight against malaria. There has been some success, but the pace of work was slower than desired and the scale was less than expected. The world now faces additional challenges, not the least of which is the emergence of drug-resistant forms of malaria.

Despite the challenges, there are great opportunities to be explored. We have access to more effective technologies to prevent and cure malaria. Countries are renewing efforts to control the disease, and there is a global consensus that more needs to be done, urgently, on a large scale and in a sustainable way.

This report translates our corporate commitment into increased efforts to control malaria. It lays the basis for a Booster Program for Malaria Control, through which the Bank will make an important contribution to malaria control in the years ahead. We will undertake this effort in support of country-led programs and in partnership with community service organizations, specialized agencies, and financiers of malaria control at all levels. Consistent with the new Global Strategic Plan of the Roll Back Malaria Partnership, the Bank's work will combine measures to increase coverage of malaria-specific interventions with effective service delivery, broader health-system development, and capacity building across multiple sectors.

A multidisciplinary Malaria Task Force prepared this report, together with the Program of Action. The Task Force included staff from across the World Bank Group, with much appreciated contributions from the International Finance Corporation. Consultations with country officials helped to shape the results-based and client-oriented approach in this strategy. Many peer reviewers, colleagues in the Roll Back Malaria Partnership Secretariat, and an External Consultative Group provided critical reviews and helpful suggestions. The Roll Back Malaria Department of the WHO provided data

**Rolling Back Malaria**

on malaria case notification and coverage with key interventions. We thank all contributors for their time and inputs.

Looking to the future, a steering committee of vice presidents in operational and corporate units will provide guidance and support for its implementation. Regional and country teams will lead the implementation of the proposed Booster Program for Malaria Control in a way that is responsive to country needs. We will monitor progress, evaluate impacts, and learn from experiences. Working with multiple partners, the proposed program will boost malaria control, foster economic growth, and accelerate progress toward the Millennium Development Goals, which are central to the Bank's overall mission of reducing poverty.

*Jean-Louis Sarbib*  
*Senior Vice President*  
*Human Development Network*  
*World Bank*

## Acknowledgments

---

This Global Strategy and Program of Action was prepared with guidance from Jean-Louis Sarbib (Senior Vice President, Human Development Network) and substantial contributions from the senior leadership, managers, and staff of the World Bank Group, including Gobind Nankani (Vice President, Africa Region), Praful Patel (Vice President, South Asia Region), Jacques Baudouy (Director, Health, Nutrition, and Population), Kei Kawabata (Sector Manager, Health, Nutrition, and Population), and Ok Pannenberg (Senior Health Adviser, Africa Region). Davidson Gwatkin and Keith Hansen made helpful contributions. Members of the Human Development Network Council provided informal advice prior to the Decision Meeting in December 2004.

Olusoji Adeyi managed the work program and led the Malaria Task Force.

### The Malaria Task Force

Alexandre Abrantes	Sector Manager, AFTH2
Anabela Abreu	Sector Manager, SASHD
F. Ayo Akala	Public Health Specialist, MNSHD
Chantal Andriamilamina	Investment Officer, IFC
Lawrence Barat	Consultant
Enis Baris	Senior Health Specialist, ECSHD
Donald Bundy	Lead Education Specialist, HDNED
Gilles Dussault	Senior Health Specialist, WBIHD
John Garrison	Senior Communications Officer, EXTIA
Phil Hay	Communications Advisor, HDNOP
Stevan Jackson	Communications Associate, HDNOP
Eva Jarawan	Lead Health Specialist, AFTH3
Monique Mrazek	Young Professional, IFC
Egbe Osifo	Sector Manager, WBIHD
Mead Over	Lead Economist (Health), DECRG
Maryse Pierre-Louis	Lead Health Specialist, AFTH2
Agnes Soucat	Lead Economist, AFTHD
Jean Jacques de St. Antoine	Lead Operations Officer, AFTH1

**Rolling Back Malaria**

Yolanda Tayler	Lead Specialist, Procurement/Health, OPCPR
Denise Vaillancourt	Senior Evaluation Officer, OEDSG

**Secretariat**

Olusoji Adeyi	Coordinator, Global Partnerships for Communicable Diseases, HDNHE
Yvette Atkins	Program Assistant, HDNHE
Suprotik Basu	Public Health Specialist, HDNHE (seconded from RBM Secretariat)
Pablo Gottret	Senior Economist, HDNHE
Samantha Naidoo	Health Specialist (YP), HDNHE
Andreas Seiter	Global Pharmaceuticals Industry Fellow, HDNHE

*Disclaimer: Peer reviewers and members of the External Consultative Group bear no responsibility for the contents of this Global Strategy and Program of Action.*

**Peer Reviewers****Internal**

Benjamin Loevinsohn	Senior Public Health Specialist, SASHD
Gebre Okubagzhi	Senior Health Specialist, AFTH3
Mead Over	Lead Economist, DECRG
Susan Stout	Manager, Results Secretariat
Christopher Walker	Lead Health Specialist, AFTH1

**External**

Dean Jamison	Chair, Institute of Medicine Board on Global Health
Adetokunbo Lucas	Adjunct Professor, Harvard University. Formerly Director, UNDP/World Bank/ WHO Special Program for Research and Training in Tropical Diseases

Innocent Nyaruhirira	Minister of State for HIV/AIDS and Other Epidemics, Rwanda
Richard Steketee	Formerly Chief, Malaria Branch, United States Centers for Disease Control and Prevention

**External Consultative Group**

George Amofah	Chair, RBM Partnership Board and Director, Public Health Division, Ghana Health Service
James Banda	RBM Partnership Secretariat
Dennis Carroll	USAID
Awa Coll-Seck	RBM Executive Secretary (former Minister of Health, Senegal)
Don de Savigny	Swiss Tropical Institute
Laurie Garrett	Council on Foreign Relations
Melville George	WHO Representative, Ghana
Salim Habayeb	WHO Representative, India
Chris Hentschel	Medicines for Malaria Venture
James Herrington	United Nations Foundation
Gerhard Hesse	Bayer Environmental Science
Fatoumata Nafu-Traore	WHO, Geneva (former Minister of Health, Mali)
Frank Nyonator	Ghana Health Service
Nosa Orobato	John Snow Inc., Uganda
Regina Rabinovich	Bill and Melinda Gates Foundation
Jeffrey Sachs	Columbia University
Alec Soucy	Results Canada
Awash Teklehaimonot	Columbia University
Susan Zimicki	Academy for Educational Development

The staff of the Office of the Publisher contributed to the quality of this document, especially Dana Vorisek.



# Abbreviations and Acronyms

---

AAA	Analytic and advisory services
ACT	Artemisinin-based combination therapy
CAS	Country assistance strategy
CDD	Community-driven development
CSO	Civil society organization
CQ	Chloroquine
DALY	Disability-adjusted life year
DEC	Development Economics Vice Presidency
DHS	Demographic and Health Surveys
EMCP	Enhanced Malaria Control Project
FTE	Full-time equivalent
GDP	Gross domestic product
GNP	Gross national product
GFATM	Global Fund to Fight AIDS, Tuberculosis and Malaria
HAMSET	HIV/AIDS, Malaria, STDs, and TB Control Project
HIPC Initiative	Highly Indebted Poor Country Initiative
IDA	International Development Association
IFC	International Finance Corporation
IRS	Indoor residual spraying
ITN	Insecticide-treated bed net
LICUS	Low Income Countries Under Stress
LLIN	Long-lasting insecticidal nets
M&E	Monitoring and evaluation
MACEPA	Malaria Control and Evaluation Project in Africa
MAP	Multi-country HIV/AIDS Program
MDGs	Millennium Development Goals
MICS	Multiple Indicator Cluster Surveys
MTEF	Medium-Term Expenditure Framework
NGO	Nongovernmental organization
NMCP	National Malaria Control Program
PRSC	Poverty Reduction Support Credit
PRSP (I-PRSP)	Poverty Reduction Strategy Paper (Interim Poverty Reduction Strategy Paper)
RBM	Roll Back Malaria Partnership
SP	Sulfadoxine pyrimethamine
SWAp	Sectorwide approach
UNDP	United Nations Development Program
UNICEF	United Nations Children's Fund

USAID	U.S. Agency for International Development
VPU	Vice presidential unit
WHO	World Health Organization
WHO AFRO	World Health Organization Regional Office for Africa
WPRO	WHO Office for the Western Pacific